Skip to Main Content


Skip Nav Destination

Multiple Myeloma and Plasma Disorders

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to multiple myeloma and plasma disorders.


Insights Into the Burden of MM on Caregivers

A significant proportion of caregivers of patients with multiple myeloma (MM) experience substantial psychological distress and believe that their loved one’s disease is curable, according to study findings published in Blood Advances....

Subcutaneous Versus IV Daratumumab May Be a Preferred Treatment Choice in Patients With R/R MM

Subcutaneously administered daratumumab, the standard formulation used in clinical practice, was associated with a similar efficacy and safety profile as intravenous (IV) daratumumab but also had fewer infusion-related reactions and shorter administration time in this population...

Elranatamab Results in 61% ORR in Patients With R/R MM in Phase II Study

Elranatamab is a humanized bispecific antibody that targets BCMA-expressing MM cells and CD3-expressing T cells. ...

MajesTEC-1 Results Show Teclistamab Elicits Durable Responses in Patients With R/R MM

In patients with relapsed/refractory multiple myeloma (R/R MM), treatment with teclistamab, a humanized B-cell maturation antigen (BCMA) and CD3 bispecific antibody, resulted in deep responses that can be durable...

Patient-Tailored Therapeutic Strategies Needed in Newly Diagnosed MM

Patients with newly diagnosed multiple myeloma (MM) who received a combination therapy of lenalidomide, bortezomib, and dexamethasone (RVd) had a 53% higher risk of disease progression or death compared to those who received RVd and also underwent an autologous hematopoietic cell transplant (AHCT). ...

BCMA-Directed CAR-T Therapy Effective in Relapsed/Refractory Multiple Myeloma

The fully human B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy CT103A demonstrated activity with an acceptable safety profile in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Updated Phase I Results Show Response in R/R MM With Talquetamab, Recommend Phase II Doses

The first-in-class bispecific antibody talquetamab has an anticipated safety profile and demonstrated efficacy for the treatment of relapsed/refractory (R/R) multiple myeloma (MM) in heavily pretreated patients...

Oral Triplet Regimen Including Ixazomib Inferior to Other Treatments for PFS in Newly Diagnosed MM

Ixazomib, the first-in-class oral proteasome inhibitor, is approved for the treatment of relapsed or refractory multiple myeloma (MM) in combination with lenalidomide and dexamethasone. ...

PET/CT May Add Prognostic Value to Biochemical Assessment in Newly Diagnosed MM

A negative positron emission tomography (PET)/computed tomography (CT) signal at six months is associated with improved survival outcomes in patients with newly diagnosed multiple myeloma (MM), according to study findings published in Blood Advances. ...

Dara-KRd With MRD Response-Adapted Therapy Leads to High MRD Negativity for Newly Diagnosed MM

Treatment with quadruplet therapy in combination with autologous hematopoietic cell transplantation (AHCT) and measurable residual disease (MRD) response-adapted consolidation, resulted in high rates of MRD negativity in patients with newly diagnosed multiple myeloma (MM). ...


Connect with us:

September 2022


Close Modal

or Create an Account

Close Modal
Close Modal